RADX

Radiopharm Theranostics Limited American Depositary Shares

4.70 USD
-0.35
6.93%
Updated Jun 20, 10:24 AM EDT
1 day
-6.93%
5 days
-14.55%
1 month
12.44%
3 months
-19.24%
6 months
7.06%
Year to date
1.29%
1 year
-73.40%
5 years
-73.40%
10 years
-73.40%
 

About: Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

0
Funds holding %
of 7,302 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.01% less ownership

Funds ownership: 0.02% [Q4 2024] → 0.01% (-0.01%) [Q1 2025]

15% less capital invested

Capital invested by funds: $1.94M [Q4 2024] → $1.65M (-$290K) [Q1 2025]

25% less funds holding

Funds holding: 4 [Q4 2024] → 3 (-1) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$12
155%
upside
Avg. target
$12
155%
upside
High target
$12
155%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Maxim Group
Michael Okunewitch
155%upside
$12
Buy
Initiated
1 May 2025

Financial journalist opinion

We haven’t received any recent news articles for RADX.

Charts implemented using Lightweight Charts™